1. Scrip
  2. >>Business

Stivarga Filings Reinforce Bayer’s HCC Position, For Now

 
• By Alexandra Shimmings

Bayer has filed Stivarga for use in second-line advanced liver cancer, and is set to dominate this indication in the near future, although serious competition lies in wait.

Cancer-cells-pink-color_1200x675
• Source: Shutterstock

Bayer AG has filed for supplemental regulatory approval of its oral multikinase inhibitor Stivarga (regorafenib) for use in second-line advanced liver cancer in the three major markets of the US, EU and Japan, setting up the company for market domination in this disease for several years to come.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.